My Nonprofit Reviews

I have interacted with FRAXA since 2006, acting as a researcher working in development of new medicines for Fragile X Syndrome. What attracted me to FRAXA in the first instance, and continues to be true today, is the role FRAXA has played in putting Fragile X Syndrome on the radar of the pharmaceutical industry. I can remember the days when there were no clinical stage investigations of novel potential therapeutic approaches to Fragile X Syndrome. Now there is an industry wide pipeline of programs in development across many companies. I think it is a simple truth that without FRAXA this would not be the case. The initiatives FRAXA has in place have, and continues to be, crucial to this critical mass of effort to find new options for people with lives touched by Fragile X Syndrome.